Zobrazeno 1 - 10
of 59
pro vyhledávání: ''
Autor:
Courtney Nicole Miller-Chism, Harinder S. Juneja, Curtis Lachowiez, Hilary Y. Ma, Martha P. Mims, Wei Qiao, Onyebuchi Ononogbu, Mark M. Udden, Effrosyni Apostolidou
Publikováno v:
Clin Lymphoma Myeloma Leuk
Despite therapeutic advances and improvement in outcomes of patients with acute lymphoblastic leukemia, as reported by specialized centers, healthcare disparities exist. This is a retrospective cohort analysis of the clinical outcomes of 146 patients
Autor:
Jean El Cheikh, Iman Abou Dalle, Jeries Kort, Farouk Al Chami, Maya Charafeddine, Haidar El Darsa, Rola El Sayed, Ali Ibrahim, Ali Bazarbachi
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:711-719
Background Intensified immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) improves outcomes in younger adults with diffuse large B-cell lymphomas (DLBCL) compared with R-CHOP. Due to vinde
Autor:
Rasmus T. Hoeg, Matthew E. Tenold, Rajeev Krishnan, Mehrdad Abedi, Brian A. Jonas, Aaron S. Rosenberg, Joseph Tuscano, Benjamin N Moskoff
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e611-e618
Background FLAG ± Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin), is a salvage chemotherapy regimen for relapsed or refractory (R/R) acute myeloid leukemia (AML), with complete remission (CR) rates historically
Autor:
Mazyar Shadman, Allison M. Winter, Yazeed Samara, Paolo Caimi, Ryan C. Lynch, Stephen D. Smith, Brian T. Hill, Caron A. Jacobson, Matthew Mei, Alex F. Herrera, Filippo Milano, Ajay K. Gopal, Chaitra S. Ujjani, Paolo Lopedote, Austin I. Kim
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:170-175
Polatuzumab vedotin is approved therapy in the United States for relapsed/refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab (Pola+BR). However, the safety and efficacy of Pola+BR outside of a clinical trial setti
Autor:
Tulika Seth, Manoranjan Mahapatra, Sudip Kumar Datta, Gopila Gupta, Ashish Datt Upadhyay, Richa Juneja, Vikas Garg, Renu Saxena
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e99-e104
Tumor lysis syndrome (TLS) is a metabolic emergency in hematology patients. The recommended dose of rasburicase for the management of TLS is 0.2 mg/kg per day for 5 days, which is cost prohibitive for many patients. We sought to determine the efficac
Autor:
Jörn C. Albring, Christoph Schliemann, Matthias Stelljes, Christoph Groth, Patrick Stelmach, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Klaus Wethmar, Jan-Henrik Mikesch, Daniela V. Wenge
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e724-e733
Background Blinatumomab and inotuzumab ozogamicin are now widely used to treat relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Patients and Methods We have reported the clinical course of 34 adult patients with r/r B-ALL recei
Autor:
Moussab Damlaj, Mohammad Snnallah, Ayman Alhejazi, Bader Alahmari, Mohsen Alzahrani, Razan Bashir, Hind Salama, Ahmed Alaskar, Inaam Shehab Eddine
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:690-696
Background Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with cytarabine and methotrexate (hyper-CVAD) is a commonly used regimen in adults with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (
Autor:
R J Ma, Jianmin Guo, Zhongwen Liu, Xiangli Chen, L Jiang, Jie Shi, X L Yuan, Jing Yang, Zunmin Zhu, Yin Zhang, Xiaojian Zhu, Yuzhu Zang, Pingchong Lei, Shiwei Yang, Lin Zhang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e382-e391
Introduction The purpose of this study was to explore the outcomes of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) plus idarubicin (IDA) as a frontline treatment in adult patients with acute promyelocytic leukemia (APL). Patients and Met
Autor:
Aaron S. Rosenberg, Brian A. Jonas, Mehrdad Abedi, Julian R Davis, Rasmus T. Hoeg, Joseph Tuscano
Publikováno v:
Clin Lymphoma Myeloma Leuk
Clinical lymphoma, myeloma & leukemia, vol 20, iss 7
Clinical lymphoma, myeloma & leukemia, vol 20, iss 7
Introduction Everolimus and bendamustine both have single-agent activity against lymphoid hematologic malignancies. We examined this combination in a group of heavily pretreated patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and mul
Autor:
Noridza Rivera, Caroline Rivera, Idalia Liboy, Wandaly I. Pardo, Fernando Cabanillas, Pedro Gil Solivan, Mirelis Acosta
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:776-783
Purpose To evaluate the impact of lenalidomide in patients with aggressive lymphoma who experienced less than complete response (CR) or as maintenance therapy after CR after gemcitabine, rituximab, and oxaliplatin salvage chemotherapy (GROC-Rev regim